Quantcast
Last updated on April 21, 2014 at 8:49 EDT

Latest Trastuzumab Stories

2011-12-08 23:28:02

Results presented at 2011 CTRC-AACR-San Antonio Breast Cancer Symposium Initial results from an ongoing clinical trial, the first designed to examine the utility of whole-genome sequencing for triple negative breast cancer, were reported today during the CRTC-AACR San Antonio Breast Cancer Symposium. The results indicate activation of targets not previously associated with triple negative disease and could point toward new treatment strategies. Based on mutations uncovered by...

2011-12-08 22:34:34

Obese patients with early-stage HER2-positive breast cancer may have worse outcomes than patients who are normal weight or overweight, Mayo Clinic researchers found in a study presented today at the 2011 CTRC-AACR San Antonio Breast Cancer Symposium. HER2-positive breast cancer gets its name from a protein called human epidermal growth factor receptor 2 that promotes cancer cell growth. "Not only did obese women have poorer outcomes given several different therapies tested to treat...

2011-12-08 22:31:56

A large, multicenter, randomized study has shown that obese patients with HER2-positive breast cancer have larger tumors, increased lymph node involvement and, when not treated with trastuzumab, poorer long-term outcomes than normal-weight patients. This is the first time the relationship between obesity and HER2-positive breast cancer has been studied, according to Jennifer A. Crozier, M.D., a medical resident at Mayo Clinic, Jacksonville, who presented the results at the 2011 CTRC-AACR...

2011-12-08 12:55:30

Data evaluated by an independent review committee revealed that the addition of bevacizumab to trastuzumab and docetaxel significantly improved progression-free survival in HER2-positive breast cancer, despite findings from an investigator assessment that the improvement was present but statistically non-significant. Luca Gianni, M.D., director of medical oncology at the San Raffaele Cancer Center in Milano, Italy, presented results from AVEREL, a randomized, phase 3 trial, at the 2011...

2011-12-08 12:53:09

Adding pertuzumab to a combination of trastuzumab and docetaxel chemotherapy extended progression-free survival by a median of 6.1 months in patients with metastatic HER2-positive breast cancer compared with patients who received the combination therapy with placebo. Researchers conducted an international phase 3, double-blind, randomized trial, known as CLEOPATRA (CLinical Evaluation Of Pertuzumab And TRAstuzumab), in which they randomly assigned 808 patients to receive trastuzumab and...

2011-12-08 08:30:00

WORCESTER, Mass. and TORONTO, Dec. 8, 2011 /PRNewswire/ -- Generex Biotechnology Corporation (OTCBB: GNBT.OB) today announced that positive interim Phase 2 clinical data from its ongoing study of a novel Ii-Key Hybrid-based HER-2/neu Peptide Vaccine (AE37) in HER-2 expressing breast cancer patients were presented at the 34th Annual CTRC-AACR San Antonio Breast Cancer Symposium (SABCS) in San Antonio, Texas. The AE37 vaccine is being developed by its wholly-owned subsidiary,...

2011-12-07 14:36:01

One study presented at the meeting, which is being held in Budapest, Hungary, 7 to 10 December, reports on an initiative using echocardiography to document early warning signs of adverse effects from trastuzumab (Herceptin ®)´, while the other uses echocardiography to evaluate the protective role of ACE inhibitors and statins on the hearts of cancer patients². "These studies open the way for the early identification of myocardial damage at the subclinical level, thereby...

2011-12-01 19:03:26

Sequencing points to treatment protocols, results in patient benefit Triple negative breast tumors, which make up nearly 20 percent of breast cancers, do not respond to treatment with targeted therapies such as Herceptin® (trastuzumab). To investigate new options for these patients, the first clinical trial of whole-genome sequencing for women with triple negative breast cancer was initiated in March 2010, and the first results will be presented during the 2011 CTRC-AACR San Antonio...

2011-11-21 08:30:00

WORCESTER, Mass. and TORONTO, Nov. 21, 2011 /PRNewswire/ -- Generex Biotechnology Corporation (OTCBB: GNBT.OB) (www.generex.com) announced today that its wholly-owned subsidiary, Antigen Express, Inc. (www.antigenexpress.com), will present new Phase 2 clinical data from its study of a novel Ii-Key Hybrid-based HER-2/neu Peptide Vaccine (AE37) in HER-2 expressing breast cancer patients at the 34th Annual CTRC-AACR San Antonio Breast Cancer Symposium (SABCS) in San Antonio, Texas on December...

2011-11-16 08:30:00

SAN DIEGO, Nov. 16, 2011 /PRNewswire/ -- Aethlon Medical, Inc., (OTCBB:AEMD) disclosed today that its Chairman and CEO, James A. Joyce, has issued the following letter to shareholders. (Photo: http://photos.prnewswire.com/prnh/20090325/LA88762LOGO-b) To our Shareholders: Earlier this year, we introduced and began marketing the Aethlon ADAPT(TM) system, a technology platform that intersects the medical device and drug world to establish a new class of therapeutics that allow for the...